Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Jetstar to Charge for Overhead Cabin Bags From February 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
MENLO PARK, Calif., March 20, 2018 -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that company management will present an overview of the company at the 17th Annual Needham Healthcare Conference.
- Location: New York, NY
- Presentation date: Tuesday, March 27, 2018
- Presentation time: 9:30 a.m. ET
A live audio webcast and archive of the presentation will be available at http://investor.dermira.com.
About Dermira
Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions. Dermira is committed to understanding the needs of both patients and physicians and using its insight to identify and develop leading-edge medical dermatology programs. Dermira’s pipeline includes two late-stage product candidates that could have a profound impact on the lives of patients: glycopyrronium tosylate (formerly DRM04), for which a New Drug Application is under review by the U.S. Food and Drug Administration for the treatment of primary axillary hyperhidrosis (excessive underarm sweating beyond what is needed for normal body temperature regulation), and lebrikizumab, in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis. Dermira is headquartered in Menlo Park, Calif. For more information, please visit http://www.dermira.com. Follow @DermiraInc on Twitter and LinkedIn.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Dermira uses its website (www.dermira.com), LinkedIn page (https://www.linkedin.com/company/dermira-inc) and corporate Twitter account (@DermiraInc) as channels of distribution of information about its company, product candidates, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Dermira may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Dermira’s website, LinkedIn page and Twitter account in addition to following its SEC filings, press releases, public conference calls and webcasts.
Contacts:
Media:
Erica Jefferson
Vice President, Corporate Communications
650-421-7216
[email protected]
Investors:
Ian Clements, Ph.D.
Vice President, Investor Relations
650-422-7753
[email protected]
Robert H. Uhl
Westwicke Partners
Managing Director
858-356-5932
[email protected]
